ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-p ...

Core Insights - Oculis Holding AG will host an R&D Day on April 15, 2025, to provide updates on its clinical candidates and future development strategies [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema (DME), Licaminlimab for dry eye disease (DED), and Privosegtor for acute optic neuritis [16] Clinical Development Updates - The R&D Day will feature updates on the Phase 3 DIAMOND trials for OCS-01 eye drops in DME, the development plan for Licaminlimab in DED, and expanded data from the ACUITY Phase 2 trial for Privosegtor [2][3] - OCS-01 is a high concentration dexamethasone eye drop aimed at providing a non-invasive treatment for DME, addressing limitations of current invasive treatments [4][5] - Licaminlimab is an anti-TNFα eye drop candidate showing positive effects in Phase 2 trials for DED, with a genetic biomarker identified for improved response [9][10] - Privosegtor has shown neuroprotective benefits in acute optic neuritis, with orphan drug designation from both the FDA and EMA [13][14] Market Need and Impact - DME affects approximately 37 million people globally, with projections to rise to 53 million by 2040, highlighting the urgent need for effective treatments [6][8] - DED impacts over 110 million people in G7 countries, with a significant unmet need as 87% of chronic patients remain unsatisfied with current treatments [11][12] - Acute optic neuritis affects up to 8 in 100,000 people and currently lacks specific neuroprotective therapies, indicating a substantial market opportunity for Privosegtor [15]

Core Insights - Oculis Holding AG will host an R&D Day on April 15, 2025, to provide updates on its clinical candidates and business strategy [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema (DME), Licaminlimab for dry eye disease (DED), and Privosegtor for acute optic neuritis [16] Clinical Development Updates - The R&D Day will feature updates on the Phase 3 DIAMOND trials for OCS-01, the development plan for Licaminlimab in DED, and the expanded data analysis from the ACUITY Phase 2 trial for Privosegtor [2][3] - OCS-01 is a high concentration dexamethasone eye drop aimed at providing a non-invasive treatment for DME, which currently affects approximately 37 million people globally and is expected to rise to 53 million by 2040 [4][6][8] - Licaminlimab is an anti-TNFα eye drop candidate that has shown positive effects in Phase 2 trials for DED, which impacts over 110 million people in G7 countries [9][11][12] - Privosegtor has demonstrated neuroprotective benefits in acute optic neuritis, a condition affecting up to 8 in 100,000 people worldwide, and has received orphan drug designation from both the FDA and EMA [13][15] Market Need - There is a significant unmet need for effective treatments for DME and DED, as current therapies often require invasive methods or do not adequately address patient needs [8][12]

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Attachments ...

Financial Performance - The company incurred net losses of CHF 85.8 million and CHF 88.8 million for the fiscal years ended December 31, 2024 and 2023, respectively, with accumulated losses of CHF 285.6 million as of December 31, 2024[29]. - The company has no products approved for commercial sale and has not generated any revenue from product sales, with expectations of continuing significant net losses for the foreseeable future[34]. - The company anticipates substantial increases in expenses as it progresses its product candidates through clinical development and seeks regulatory approvals[31]. - The company may require additional capital for further development and commercialization of its product candidates, with no committed source of additional capital currently available[44]. - The company expects ongoing compliance with dual-listing regulations to significantly increase legal, accounting, and IT costs, negatively impacting financial performance[48]. - The company may incur substantial increases in legal, accounting, and insurance expenses due to its status as a dual-listed public company, affecting its financial condition[49]. - The company has entered into a loan agreement providing up to CHF 50.0 million in borrowing capacity, which may be increased to CHF 65.0 million[95]. - The loan agreement includes restrictions that could limit the company's operational and financial flexibility, potentially placing it at a competitive disadvantage[96]. Product Development and Regulatory Approval - The company is developing product candidates OCS-01, Licaminlimab (OCS-02), and Privosegtor (OCS-05), which are critical for its future revenue generation[40]. - The regulatory approval processes for the company's product candidates are complex and unpredictable, impacting the timeline for potential revenue generation[36]. - The clinical and commercial success of product candidates OCS-01, Privosegtor (OCS-05), and Licaminlimab (OCS-02) is uncertain and depends on successful development and regulatory approval[110]. - The ability to generate product revenues and achieve profitability is contingent on obtaining marketing approval for OCS-01, Privosegtor (OCS-05), and Licaminlimab (OCS-02)[113]. - The success of these product candidates depends on timely completion of clinical trials, regulatory agency approvals, and acceptance by patients and the medical community[114]. - The company announced topline data for Stage 1 of the DIAMOND Phase 3 clinical trial of OCS-01 in DME, which met primary and secondary endpoints with robust statistical significance, but replication in Stage 2 is uncertain[116]. - The FDA or non-U.S. regulatory agencies may require additional studies beyond those planned, which could necessitate substantial additional funding[120]. - The company may face delays or inability to commercialize product candidates due to unforeseen events during clinical trials, including administrative errors[121]. - Clinical trials may not produce statistically significant results, leading to potential abandonment or restructuring of product development programs[122]. - The company may need to suspend or terminate clinical trials if they do not comply with regulatory requirements or if adverse safety outcomes occur[124]. - Any serious adverse events could result in delays or denials of marketing approval, adversely affecting the company's financial condition and growth prospects[126]. - Clinical trials may face substantial delays or may not be completed on expected timelines, impacting regulatory approval and commercialization[138]. - The company may encounter difficulties in patient recruitment for clinical trials, which could lead to increased costs and delays in product development[139]. - Adverse events related to product candidates could result in regulatory agencies suspending or withdrawing approvals, significantly affecting the company's reputation and financial condition[133]. - The topline results reported from clinical trials may differ significantly from final results, which could harm the company's ability to obtain regulatory approval[137]. - The company relies on third-party CROs for conducting clinical trials, and any failure in compliance could lead to unreliable clinical data and additional trials being required[146]. - The FDA and other regulatory agencies may not accept data from clinical trials conducted outside the United States, potentially necessitating additional costly trials[144]. - The company announced the closure of the Phase 3 OPTIMIZE-2 trial of OCS-01 due to a third-party administrative error, affecting the trial's conduct[147]. - Regulatory agencies require regular reporting of adverse events, and failure to comply could result in severe penalties, including criminal prosecution[135]. - The company may need to conduct additional studies if product candidates undergo manufacturing or formulation changes, impacting timelines and costs[141]. - Interim and topline data from clinical trials are subject to change and should be viewed with caution until final data are available, which could lead to volatility in share prices[136]. - The company is subject to extensive regulatory obligations and scrutiny even after obtaining regulatory approval for product candidates[149]. - Manufacturing processes for product candidates must comply with cGMP regulations, requiring ongoing review and inspections[151]. Market and Competitive Landscape - The company faces significant competition in the biopharmaceutical market, which may affect its ability to successfully commercialize its product candidates[26]. - The market opportunities for the company's product candidates may be smaller than estimated, which could adversely affect sales growth[100]. - The competitive landscape includes established therapies for conditions targeted by the company, making it challenging to persuade physicians and payors to switch to new products[186][187][188]. - The company lacks a sales and marketing infrastructure, which may hinder its ability to commercialize products effectively if approved[181]. - The company may face competition from generic products, which could significantly impact sales and market acceptance of its branded products[191]. - The company must navigate complex reimbursement policies that vary widely and are subject to change, affecting pricing and market access[175][177]. - Future mergers and acquisitions in the pharmaceutical industry may concentrate resources among competitors, increasing competitive pressures[192]. Operational Risks - The company relies on third-party contractors for the supply, manufacture, and distribution of clinical drug supplies, which poses risks to its operations[26]. - The company relies on third-party manufacturers for product candidates, and disruptions in their operations could delay marketing and development efforts[57]. - The company is dependent on licenses for development and commercialization rights to key product candidates, which could be terminated if obligations are not met[208]. - The company has obligations under various license agreements, including milestone payments and royalties, which could impact financial resources[209]. - Any failure to comply with license agreements could result in loss of rights to important intellectual property, adversely affecting commercialization efforts[210]. - The company faces risks related to the reliance on third-party suppliers for key raw materials, which could harm manufacturing capabilities[207]. - The ability to scale up production of product candidates is critical, and failure to do so could lead to delays in development and commercialization[205]. - The company may encounter difficulties in production due to reliance on third-party manufacturers, affecting the supply of product candidates[204]. - The company faces potential challenges in maintaining licensing arrangements due to disputes over intellectual property, which could hinder the development and commercialization of product candidates[213]. - Established companies may have a competitive advantage in acquiring third-party intellectual property rights, impacting the company's ability to license necessary technologies[214]. - The company risks losing rights to sublicensed patent rights if parent licenses terminate, which could adversely affect its competitive position and financial condition[215]. - Current and future licenses may not provide exclusive rights to use licensed intellectual property, potentially allowing competitors to develop similar products[216]. - Limitations on utilizing acquired or licensed technologies could delay new product introductions and impair the company's ability to market and sell product candidates[217]. Cybersecurity and Data Privacy - The company has experienced unsuccessful phishing attempts and anticipates continued threats to its information technology systems[67]. - The company may face challenges in integrating acquired entities into its information technology environment, exposing it to additional cybersecurity risks[64]. - The company has implemented security measures to protect against incidents but cannot guarantee their effectiveness[66]. - The company may need to modify its business activities to protect against security incidents, which could divert resources from clinical trial activities[68]. - The company may face significant costs and adverse consequences due to data privacy and security obligations, including potential fines and penalties[70]. - Non-compliance with data privacy laws could lead to government investigations, litigation, and reputational harm, impacting revenue and profits[73]. - Under the GDPR, companies could face fines of up to €20 million or 4% of annual global revenue, whichever is greater, for non-compliance[78]. - The company is subject to various U.S. state privacy laws, such as the California Consumer Privacy Act, which allows for significant statutory damages for data breaches[77]. - The company may incur increased compliance costs and legal risks due to evolving data protection laws and regulations[88]. - The company’s marketing strategies may be adversely affected by stringent opt-in consent requirements for data processing under EU laws[83]. Human Resources and Compliance - The company had 49 employees as of December 31, 2024, and may need additional resources to support its growth strategy[50]. - The company faces intense competition for qualified personnel, which may hinder its ability to achieve research, development, and commercialization objectives[47]. - The company may encounter substantial costs and management distractions from potential securities class action litigation due to stock price volatility[98]. - The company may need to purchase insurance coverage as it expands clinical trials, which is becoming increasingly expensive and restrictive[194]. - Collaborations with third parties for product development may not be successful, impacting the company's ability to capitalize on market potential[195].

Exhibit 99.2 Oculis Holding AG Consolidated Financial Statements Table of Contents | Report of the statutory auditor to the General Meeting | 1 | | --- | --- | | Consolidated Statements of Financial Position as of December 31, 2024 and 2023 | 4 | | Consolidated Statements of Loss for the years ended December 31, 2024, 2023 and 2022 | 5 | | Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022 | 6 | | Consolidated Statements of Changes in Equity for the years ende ...

Core Viewpoint - Oculis Holding AG reported significant clinical advancements and financial results for the year 2024, highlighting its commitment to developing innovative treatments for ophthalmic and neuro-ophthalmic diseases, with a strong focus on executing its late-stage clinical portfolio in 2025 [2][6][18] Clinical Highlights and Upcoming Milestones - The company achieved positive Phase 2 topline results from the ACUITY trial for Privosegtor (OCS-05) in acute optic neuritis and the RELIEF trial for Licaminlimab (OCS-02) in dry eye disease [2][6] - Enrollment for the Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema (DME) is on track to be completed in the coming months, with top-line data expected in the first half of 2026 [7] - A $100 million equity financing was successfully completed to support the advancement of the clinical portfolio [6][8] Financial Highlights - As of December 31, 2024, the company had total cash, cash equivalents, and short-term investments of CHF 98.7 million or $109.0 million, an increase from CHF 91.7 million or $108.9 million at the end of 2023 [5][8] - The net loss for Q4 2024 was CHF 28.7 million or $32.6 million, compared to CHF 12.5 million or $14.1 million for the same period in 2023 [10][14] - For the full year 2024, the net loss was CHF 85.8 million or $97.4 million, a slight decrease from CHF 88.8 million or $98.8 million in 2023 [10][14] Research and Development Expenses - Research and development expenses for Q4 2024 were CHF 11.8 million or $13.4 million, up from CHF 8.0 million or $9.0 million in Q4 2023 [10][14] - For the full year 2024, research and development expenses totaled CHF 52.1 million or $59.1 million, compared to CHF 29.2 million or $32.6 million in 2023 [10][14] Future Outlook - The company plans to provide further updates on its business and pipeline development during the R&D Day scheduled for April 15, 2025, in New York City [4][6]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company will present at the Leerink Global Healthcare Conference on March 11, 2025, at 3:00 PM ET [1] - Oculis has a differentiated pipeline including innovative product candidates such as OCS-01, OCS-05, and OCS-02 [3] Company Overview - Oculis is headquartered in Switzerland and has operations in the U.S. and Iceland [3] - The management team has a successful track record and is supported by leading international healthcare investors [3] Upcoming Events - The company will be available for one-on-one meetings during the conference, and interested investors can contact their representatives [1] - A live webcast of the fireside chat will be accessible on the Oculis website [2]

Core Viewpoint - Oculis Holding AG has announced an underwritten offering of 5,000,000 ordinary shares priced at $20.00 per share, aiming for total gross proceeds of $100 million to support its clinical development pipeline and general corporate purposes [1][3]. Group 1: Offering Details - The offering is oversubscribed and is expected to close on or about February 18, 2025, pending customary closing conditions [2]. - The new shares will be issued from the Company's existing capital band, increasing the total number of registered shares to 53,943,700 [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of the neuroprotective candidate Privosegtor (OCS-05) and for working capital and general corporate purposes [3]. Group 3: Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema and Licaminlimab (OCS-02) for dry eye disease [5].

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in short-term investing, highlighting that while price momentum can be profitable, it requires solid fundamentals to maintain that momentum. Group 1: Stock Performance - Oculis Holding AG (OCS) has shown a solid price increase of 27.2% over the past 12 weeks, indicating strong investor interest [4] - The stock has also increased by 31.4% over the last four weeks, suggesting that the upward trend is still intact [5] - OCS is currently trading at 94% of its 52-week high-low range, indicating a potential breakout [5] Group 2: Fundamental Strength - OCS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6] - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7] Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like OCS that have sufficient fundamental strength to maintain their recent uptrend [3] - The article suggests that there are several other stocks passing through this screen, indicating potential investment opportunities [8]